<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
(AMENDMENT NO. 1)
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): JULY 21, 1998
GENEMEDICINE, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-24572 76-0355802
(Commission File No.) (IRS Employer Identification No.)
8301 NEW TRAILS DRIVE
THE WOODLANDS, TEXAS 77381-4248
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (281) 364-1150
<PAGE>
The undersigned hereby amends Item 7 of its Current Report on Form 8-K filed
with the Commission on July 27, 1998.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(C) EXHIBITS.
16 Letter dated July 24, 1998 from Arthur Andersen LLP, the
Registrant's former accountants, to the SEC.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEMEDICINE, INC.
Dated: August 3, 1998 By: Richard A. Waldron
-------------------------
Richard A. Waldron
Chief Financial Officer
<PAGE>
INDEX TO EXHIBITS
16 Letter dated July 24, 1998 from Arthur Andersen, the
Registrant's former accountants, to the SEC.
<PAGE>
EXHIBIT 16
July 24, 1998
Office of the Chief Accountant
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Dear Sir/Madam:
We have read Item 4 included in the Form 8-K dated July 21, 1998 of
GeneMedicine, inc. filed with the Securities and Exchange Commission and are in
agreement with the statements contained therein.
Very truly yours,
ARTHUR ANDERSEN LLP
